Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC)

METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction)

RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk

CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials

Year of Publication: 2020
Contained in: Annals of the rheumatic diseases Vol. 79, No. 10 (2020), p. 1286-1289
All journal articles: Search for all articles in this journal
Language: English
Contributors: Scarsi, Mirko | Author
Piantoni, Silvia
Colombo, Enrico
Airó, Paolo
Richini, Donata
Miclini, Marco
Bertasi, Valeria
Bianchi, Marta
Bottone, Damiano
Civelli, Patrizia
Cotelli, Maria-Sofia
Damiolini, Ezio
Galbassini, Gloria
Gatta, Diego
Ghirardelli, Maria-Laura
Magri, Roberto
Malamani, Paola
Mendeni, Monia
Molinari, Stefano
Morotti, Andrea
Salada, Luisa
Turla, Marinella
Vender, Angiola
Tincani, Angela
Brucato, Antonio
Franceschini, Franco
Furloni, Roberto
Andreoli, Laura
Full text access:
Electronic availability is being checked...
Links: Full Text (dx.doi.org)
Keywords: 2494G1JF75
4QWG6N8QKH
7S5I7G3JQL
Journal Article
O3J8G9O825
SML2Y3J35T
anti-inflammatory agents, non-steroidal
antirheumatic agents
communicable diseases, imported
inflammation
lopinavir-ritonavir drug combination
therapeutics
Additional Keywords: Aged
Aged, 80 and over
Anti-Inflammatory Agents
Antiviral Agents
Betacoronavirus
Case-Control Studies
Cohort Studies
Colchicine
Coronavirus Infections
Dexamethasone
Drug Combinations
Enzyme Inhibitors
Female
Hospitalization
Humans
Hydroxychloroquine
Italy
Lopinavir
Male
Middle Aged
Pandemics
Pneumonia, Viral
Proof of Concept Study
Proportional Hazards Models
Respiratory Distress Syndrome, Adult
Ritonavir
Survival Rate
ISSN: 1468-2060
Note: Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Notes: Date Completed 24.09.2020
Date Revised 06.10.2020
published: Print-Electronic
Citation Status MEDLINE
Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
PMID:
    32732245
Physical Description: Online-Ressource
ID (e.g. DOI, URN): 10.1136/annrheumdis-2020-217712
more publication details ...

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 06963nma a2201549 c 4500
001 NLM314004130
003 DE-601
005 20201006213645.0
007 cr uuu---uuuuu
008 200731s2020 000 0 eng d
024 7 |a 10.1136/annrheumdis-2020-217712  |2 doi 
028 5 2 |a pubmed20n1422.xml 
035 |a (DE-599)NLM32732245 
040 |b ger  |c GBVCP 
041 0 |a eng 
100 1 |a Scarsi, Mirko 
245 1 0 |a Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome  |h Elektronische Ressource 
300 |a Online-Ressource 
500 |a Date Completed 24.09.2020 
500 |a Date Revised 06.10.2020 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
500 |a Copyright: From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine 
520 |a © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 
520 |a OBJECTIVES: The outbreak of COVID-19 posed the issue of urgently identifying treatment strategies. Colchicine was considered for this purpose based on well-recognised anti-inflammatory effects and potential antiviral properties. In the present study, colchicine was proposed to patients with COVID-19, and its effects compared with 'standard-of-care' (SoC) 
520 |a METHODS: In the public hospital of Esine, northern Italy, 140 consecutive inpatients, with virologically and radiographically confirmed COVID-19 admitted in the period 5-19 March 2020, were treated with 'SoC' (hydroxychloroquine and/or intravenous dexamethasone; and/or lopinavir/ritonavir). They were compared with 122 consecutive inpatients, admitted between 19 March and 5 April 2020, treated with colchicine (1 mg/day) and SoC (antiviral drugs were stopped before colchicine, due to potential interaction) 
520 |a RESULTS: Patients treated with colchicine had a better survival rate as compared with SoC at 21 days of follow-up (84.2% (SE=3.3%) vs 63.6% (SE=4.1%), p=0.001). Cox proportional hazards regression survival analysis showed that a lower risk of death was independently associated with colchicine treatment (HR=0.151 (95% CI 0.062 to 0.368), p<0.0001), whereas older age, worse PaO2/FiO2, and higher serum levels of ferritin at entry were associated with a higher risk 
520 |a CONCLUSION: This proof-of-concept study may support the rationale of use of colchicine for the treatment of COVID-19. Efficacy and safety must be determined in controlled clinical trials 
611 2 7 |a Journal Article  |2 gnd 
653 2 |a Aged  |6 D000368 
653 2 |a Aged, 80 and over  |6 D000369 
653 2 |a Anti-Inflammatory Agents  |6 D000893  |a *therapeutic use  |6 Q000627 
653 2 |a Antiviral Agents  |6 D000998  |a therapeutic use  |6 Q000627 
653 2 |a Betacoronavirus  |6 D000073640 
653 2 |a Case-Control Studies  |6 D016022 
653 2 |a Cohort Studies  |6 D015331 
653 2 |a Colchicine  |6 D003078  |a *therapeutic use  |6 Q000627 
653 2 |a Coronavirus Infections  |6 D018352  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188  |a mortality  |6 Q000401 
653 2 |a Dexamethasone  |6 D003907  |a therapeutic use  |6 Q000627 
653 2 |a Drug Combinations  |6 D004338 
653 2 |a Enzyme Inhibitors  |6 D004791  |a therapeutic use  |6 Q000627 
653 2 |a Female  |6 D005260 
653 2 |a Hospitalization  |6 D006760 
653 2 |a Humans  |6 D006801 
653 2 |a Hydroxychloroquine  |6 D006886  |a therapeutic use  |6 Q000627 
653 2 |a Italy  |6 D007558 
653 2 |a Lopinavir  |6 D061466  |a therapeutic use  |6 Q000627 
653 2 |a Male  |6 D008297 
653 2 |a Middle Aged  |6 D008875 
653 2 |a Pandemics  |6 D058873 
653 2 |a Pneumonia, Viral  |6 D011024  |a complications  |6 Q000150  |a *drug therapy  |6 Q000188  |a mortality  |6 Q000401 
653 2 |a Proof of Concept Study  |6 D000075082 
653 2 |a Proportional Hazards Models  |6 D016016 
653 2 |a Respiratory Distress Syndrome, Adult  |6 D012128  |a *drug therapy  |6 Q000188  |a etiology  |6 Q000209  |a mortality  |6 Q000401 
653 2 |a Ritonavir  |6 D019438  |a therapeutic use  |6 Q000627 
653 2 |a Survival Rate  |6 D015996 
655 7 |a anti-inflammatory agents, non-steroidal  |2 gnd 
655 7 |a antirheumatic agents  |2 gnd 
655 7 |a communicable diseases, imported  |2 gnd 
655 7 |a inflammation  |2 gnd 
655 7 |a therapeutics  |2 gnd 
655 7 |a Anti-Inflammatory Agents  |2 gnd 
655 7 |a Antiviral Agents  |2 gnd 
655 7 |a Drug Combinations  |2 gnd 
655 7 |a Enzyme Inhibitors  |2 gnd 
655 7 |a lopinavir-ritonavir drug combination  |2 gnd 
655 7 |a Lopinavir  |2 gnd 
655 7 |a 2494G1JF75  |2 gnd 
655 7 |a Hydroxychloroquine  |2 gnd 
655 7 |a 4QWG6N8QKH  |2 gnd 
655 7 |a Dexamethasone  |2 gnd 
655 7 |a 7S5I7G3JQL  |2 gnd 
655 7 |a Ritonavir  |2 gnd 
655 7 |a O3J8G9O825  |2 gnd 
655 7 |a Colchicine  |2 gnd 
655 7 |a SML2Y3J35T  |2 gnd 
689 0 0 |A f  |a Journal Article 
689 0 |5 DE-601 
689 1 0 |a anti-inflammatory agents, non-steroidal 
689 1 1 |a antirheumatic agents 
689 1 2 |a communicable diseases, imported 
689 1 3 |a inflammation 
689 1 4 |a therapeutics 
689 1 |5 DE-601 
689 2 0 |a Anti-Inflammatory Agents 
689 2 1 |a Antiviral Agents 
689 2 2 |a Drug Combinations 
689 2 3 |a Enzyme Inhibitors 
689 2 4 |a lopinavir-ritonavir drug combination 
689 2 5 |a Lopinavir 
689 2 6 |A r  |a 2494G1JF75 
689 2 7 |a Hydroxychloroquine 
689 2 8 |A r  |a 4QWG6N8QKH 
689 2 9 |a Dexamethasone 
689 2 X |A r  |a 7S5I7G3JQL 
689 2 X |a Ritonavir 
689 2 X |A r  |a O3J8G9O825 
689 2 X |a Colchicine 
689 2 X |A r  |a SML2Y3J35T 
689 2 |5 DE-601 
700 1 |a Piantoni, Silvia 
700 1 |a Colombo, Enrico 
700 1 |a Airó, Paolo 
700 1 |a Richini, Donata 
700 1 |a Miclini, Marco 
700 1 |a Bertasi, Valeria 
700 1 |a Bianchi, Marta 
700 1 |a Bottone, Damiano 
700 1 |a Civelli, Patrizia 
700 1 |a Cotelli, Maria-Sofia 
700 1 |a Damiolini, Ezio 
700 1 |a Galbassini, Gloria 
700 1 |a Gatta, Diego 
700 1 |a Ghirardelli, Maria-Laura 
700 1 |a Magri, Roberto 
700 1 |a Malamani, Paola 
700 1 |a Mendeni, Monia 
700 1 |a Molinari, Stefano 
700 1 |a Morotti, Andrea 
700 1 |a Salada, Luisa 
700 1 |a Turla, Marinella 
700 1 |a Vender, Angiola 
700 1 |a Tincani, Angela 
700 1 |a Brucato, Antonio 
700 1 |a Franceschini, Franco 
700 1 |a Furloni, Roberto 
700 1 |a Andreoli, Laura 
773 0 8 |i in  |t Annals of the rheumatic diseases  |g Vol. 79, No. 10 (2020), p. 1286-1289  |q 79:10<1286-1289  |w (DE-601)NLM000174114  |x 1468-2060 
856 4 1 |u http://dx.doi.org/10.1136/annrheumdis-2020-217712  |3 Volltext 
912 |a GBV_NLM 
951 |a AR 
952 |d 79  |j 2020  |e 10  |b 18  |c 10  |h 1286-1289